<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04243837</url>
  </required_header>
  <id_info>
    <org_study_id>LYT-100-2020-01</org_study_id>
    <nct_id>NCT04243837</nct_id>
  </id_info>
  <brief_title>LYT-100 in Healthy Volunteers and BCRL</brief_title>
  <official_title>A Phase 1 Multiple Ascending Dose and Food Effect Study in Healthy Volunteers to Determine the Pharmacokinetics and Maximally Tolerated Dose of Deupirfenidone (LYT-100) Followed by a Randomized Double-Blind Placebo-Controlled Phase 2a in Patients With Breast Cancer-Related Upper Limb Secondary Lymphoedema</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PureTech</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novotech (Australia) Pty Limited</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>PureTech</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Part 1 is a multiple ascending dose trial in healthy volunteers (HV) of LYT-100 to determine&#xD;
      safety, tolerability, and pharmacokinetic (PK) profile under fed conditions.&#xD;
&#xD;
      Part 2 is a single dose safety, tolerability, and PK trial in HV of LYT-100 under fed and&#xD;
      fasted conditions.&#xD;
&#xD;
      Part 3 is a trial of up to 6-months duration for safety, tolerability, clinical efficacy&#xD;
      assessments, PK and biomarkers analysis in breast carcinoma patients with secondary&#xD;
      lymphoedema&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Part 1: This is a randomised, double-blind, placebo-controlled, multiple ascending dose&#xD;
      design to assess the safety, tolerability and PK profile of multiple doses of LYT-100&#xD;
      administered under fed conditions at steady state in healthy participants. Up to 4 dosing&#xD;
      cohorts are planned.&#xD;
&#xD;
      Part 2: A dose level below the MTD in Part 1 will be used in Part 2. Subjects will be&#xD;
      administered a single dose of their assigned treatment under fasting conditions followed by a&#xD;
      wash out period then they will receive a single dose of the same assigned treatment under fed&#xD;
      conditions. This will permit a comparison of the PK profile and bioavailability in both fed&#xD;
      and fasted states. .&#xD;
&#xD;
      Part 3: Once the optimal dose and regimen is determined with or without food, Part 3 will&#xD;
      follow with a randomised, double-blinded, placebo controlled design that will assess the&#xD;
      safety, tolerability, and secondarily clinical efficacy of LYT-100 over a period of up to&#xD;
      6-months of dosing in breast carcinoma patients with secondary lymphoedema following sentinel&#xD;
      lymph node biopsy and/or axillary node dissection, with or without radiation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2020</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Part 1 consists of 5 cohorts with active treatment or placebo Part 2 consists of 1 cohort with active treatment or placebo Part 3 consists of 1 cohort with active treatment or placebo</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>Part 1 and Part 2 are double-blind during the data collection. Determination for dose escalation maybe made under unblinded conditions by assessors.&#xD;
Part 3 is double-blinded</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability: treatment-emergent adverse events (TEAEs)</measure>
    <time_frame>7 days (main time frame)</time_frame>
    <description>Evaluate the safety and tolerability of LYT-100 as measured by TEAEs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Use pharmacokinetics to characterize the plasma concentration of LYT-100</measure>
    <time_frame>7 days (main time frame)</time_frame>
    <description>Measure observed concentration of LYT-100 in blood plasma</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy signals of LYT-100</measure>
    <time_frame>6 months</time_frame>
    <description>Explore efficacy signals of LYT-100 in breast cancer patients with lymphedema</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of food on the pharmacokinetic profile of LYT-100 based on plasma concentration of LYT-100</measure>
    <time_frame>2 days (main time frame)</time_frame>
    <description>Measure concentration of LYT-100 in blood plasma in fed or fasted subjects</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Breast Cancer Related Lymphoedema</condition>
  <condition>Lymphoedema</condition>
  <arm_group>
    <arm_group_label>LYT-100 in healthy volunteers with Food</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LYT-100, multiple ascending</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo in healthy volunteers with Food</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo, multiple administrations</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LYT-100 in healthy volunteers, Fasted</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LYT-100, Dose below MTD for 1 dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo in healthy volunteers, Fasted</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo, for 1 administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LYT-100 in healthy volunteers, Fed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LYT-100, Dose below MTD for 1 dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo in healthy volunteers, Fed</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo, for 1 administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LYT-100 in patients with BCRL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LYT-100 BID for 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo in patients with BCRL</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo BID for 6 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LYT-100</intervention_name>
    <description>LYT-100 is a deuterated form of pirfenidone, an orally active small molecule drug.&#xD;
HV subjects will receive multiple ascending doses, starting at 100 mg BID up to 1000 mg, with food for 5-days.</description>
    <arm_group_label>LYT-100 in healthy volunteers with Food</arm_group_label>
    <other_name>Deupirfenidone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Matching Placebo</intervention_name>
    <description>Inactive capsule(s)</description>
    <arm_group_label>Placebo in healthy volunteers with Food</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LYT-100 Food Effect</intervention_name>
    <description>LYT-100 is a deuterated form of pirfenidone, an orally active small molecule drug.&#xD;
HV subjects will receive one dose of LYT-100 or Placebo</description>
    <arm_group_label>LYT-100 in healthy volunteers, Fasted</arm_group_label>
    <arm_group_label>LYT-100 in healthy volunteers, Fed</arm_group_label>
    <arm_group_label>Placebo in healthy volunteers, Fasted</arm_group_label>
    <arm_group_label>Placebo in healthy volunteers, Fed</arm_group_label>
    <other_name>Deupirfenidone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LYT-100 BCRL</intervention_name>
    <description>BCRL patients will receive LYT-100 BID for 6 months</description>
    <arm_group_label>LYT-100 in patients with BCRL</arm_group_label>
    <other_name>Deupirfenidone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo BCRL</intervention_name>
    <description>BCRL patients will receive Placebo BID for 6 months</description>
    <arm_group_label>Placebo in patients with BCRL</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria:&#xD;
&#xD;
        Part 1 and 2: Healthy Volunteers&#xD;
&#xD;
          1. Male or female between 18 and 75 years old (inclusive) at the time of screening.&#xD;
&#xD;
          2. In good general health at screening, free from clinically significant unstable&#xD;
             medical, surgical or psychiatric illness, at the discretion of the Investigator.&#xD;
&#xD;
        Part 3: Patients with BRCL&#xD;
&#xD;
          1. Female or male between 18 and 80 years old (inclusive) at the time of informed&#xD;
             consent.&#xD;
&#xD;
          2. At least 6 months since any type of breast cancer surgery (excluding fine needle&#xD;
             aspiration biopsy [FNA]), at the time of study screening. No intention to have breast&#xD;
             reconstructive surgery, nipple reconstruction and/or tattooing during the course of&#xD;
             the study.&#xD;
&#xD;
          3. At least 3 months since completion of all types of treatment for breast cancer,&#xD;
             including but not limited to neoadjuvant, radiotherapy, chemotherapy and&#xD;
             immunotherapy, at the time of study screening.&#xD;
&#xD;
          4. At least 3 months treatment of stable adjuvant treatment with hormonal or anti-HER2&#xD;
             therapy at the time of screening, with no planned changes to this therapy throughout&#xD;
             the duration of the study.&#xD;
&#xD;
          5. Diagnosis of primary breast cancer, and without evidence of recurrence of breast&#xD;
             cancer and/or metastasis for at least 6 months since breast cancer surgery, as&#xD;
             determined at screening and baseline.&#xD;
&#xD;
          6. Documented evidence of Stage 1 or 2 lymphedema.&#xD;
&#xD;
          7. Receiving standard of care compression or agreeable to using care compression, or no&#xD;
             compression at all ≥ 4 weeks prior to screening and throughout the study.&#xD;
&#xD;
        Main Exclusion Criteria:&#xD;
&#xD;
        Part 1 and 2: Healthy Volunteers&#xD;
&#xD;
          1. History or presence of malignancy at screening or baseline, with the exception of&#xD;
             adequately treated localised skin cancer (basal cell or squamous cell carcinoma) or&#xD;
             carcinoma in-situ of the cervix.&#xD;
&#xD;
          2. Clinically significant infection within 28 days of the start of dosing, or infections&#xD;
             requiring parenteral antibiotics within the 6 months prior to screening.&#xD;
&#xD;
          3. Chronic administration (defined as more than 14 consecutive days) of&#xD;
             immunosuppressants or other immune-modifying drugs within 3 months prior to study drug&#xD;
             administration; corticosteroids are permitted at the discretion of the Investigator).&#xD;
&#xD;
          4. History or presence at screening or baseline of a condition associated with&#xD;
             significant immunosuppression&#xD;
&#xD;
        Part 3: Patients with BRCL&#xD;
&#xD;
          1. Bilateral lymphoedema or history of bilateral axillary lymph node removal (i.e.,&#xD;
             sentinel lymph node or axillary lymph node dissection), or primary lymphoedema or&#xD;
             lymphatic or vascular malformation, determined at screening.&#xD;
&#xD;
          2. Chronic administration (defined as more than 14 consecutive days) of&#xD;
             immunosuppressants or other immune-modifying drugs within 3 months prior to study drug&#xD;
             administration; corticosteroids are permitted at the discretion of the PI.&#xD;
&#xD;
          3. Recent history (in the 8 weeks prior to screening) of cellulitis, lymphangitis,&#xD;
             dermatitis, necrotizing fasciitis, or current open wounds or sores in the affected&#xD;
             extremity.&#xD;
&#xD;
          4. Stage III lymphoedema, or history of clinically diagnosed secondary lymphoedema&#xD;
             greater than 4 years, determined at screening.&#xD;
&#xD;
          5. Initiated use of compression or manual lymphatic drainage or other lymphoedema&#xD;
             therapies at the start of the study within 4 weeks of the screening visit. Rescreening&#xD;
             is allowed following a course of stable compression regimen of &gt; 4 weeks.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Christopher Korth</last_name>
    <phone>+1 617-226-4813</phone>
    <email>clinicaltrials@puretechhealth.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Michael Chen</last_name>
    <phone>+1 617-226-4813</phone>
    <email>clinicaltrials@puretechhealth.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>City of Hope National Medical Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alex Wong</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>MACRO Trials</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>91105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nima Naghshineh</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of the Sunshine Coast</name>
      <address>
        <city>Sippy Downs</city>
        <state>Queensland</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hong Shue</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ballarat Health Services</name>
      <address>
        <city>Ballarat</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lee N Teo</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nucleus Network VIC</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Flinders University</name>
      <address>
        <city>Adelaide</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ganessan Kichenadasse</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Macquarie University Health Sciences Centre</name>
      <address>
        <city>Sydney</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Helen Mackie</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>January 21, 2020</study_first_submitted>
  <study_first_submitted_qc>January 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 28, 2020</study_first_posted>
  <last_update_submitted>August 31, 2021</last_update_submitted>
  <last_update_submitted_qc>August 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Lymphedema</mesh_term>
    <mesh_term>Breast Cancer Lymphedema</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

